Literature DB >> 16225078

Recreational amitriptyline abuse.

Jacek Sein Anand1, Zygmunt Chodorowski, Bogusław Habrat.   

Abstract

UNLABELLED: Amitriptyline is a potent anticholinergics, rarely used as a drug of abuse. Two cases of amitriptyline dependency lasting for almost twelve months were described. According to the patients the abuse with amitriptyline guarantee them safety not to be uncovered by parents and doctors who systematically checked their urine with typical narcotic tests. CASE REPORT: Two patients with a history of abuse with amphetamine and clonazepam were admitted to the Clinic because of intoxication with amitriptyline. They denied the suicidal attempt and explained that they used amitriptyline in a dosage of 100 to 200 mg per day as a drug of abuse. On the day of admission one of the patients had increased the dosage up to 600 mg which caused an acute intoxication.
CONCLUSION: Antidepressants should be treated as a drugs with possible abuse ability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16225078

Source DB:  PubMed          Journal:  Przegl Lek        ISSN: 0033-2240


  3 in total

1.  A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases.

Authors:  Stefania Chiappini; Rachel Vickers-Smith; Amira Guirguis; John Martin Corkery; Giovanni Martinotti; Fabrizio Schifano
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-01

2.  Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals.

Authors:  Zofia Tylutki; Aleksander Mendyk; Sebastian Polak
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-06-25       Impact factor: 2.745

3.  Profile and use of licit psychotropic substances in the former Rabat-Sale-Zemmour-Zaër Region (Morocco): the case of tiflet city.

Authors:  Khadija Karjouh; Fatima-Zahra Azzaoui; Ahmed Ahami; Samira Boulbaroud
Journal:  Pan Afr Med J       Date:  2018-10-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.